Delivery Order SPE2DB22D1202-SPE2DB25FVFW3
- Not listed
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $1,921.89 by the Defense Logistics Agency (DLA) on July 31, 2025, for the supply of Veozah 45 mg tablets (30-count packaging). The contract carries a firm fixed price structure with no set-aside designation, indicating competitive award. The pharmaceutical product will be performed at the contractor's Conshohocken facility, with an ultimate completion date of August 1, 2025. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Veozah 45 mg tablets (30-count units) with a ceiling value of $17,319.74. This firm fixed-price delivery order, awarded on July 24, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award carries no set-aside designation and will be performed at the contractor's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $1,496.63 on July 28, 2025, with a completion date of July 29, 2025. This non-set-aside contract procures VEOZAH 45 mg tablets in a 30-count package under a firm fixed-price arrangement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $1,593.58 delivery order to AmerisourceBergen Drug Corp for VEOZAH 45 mg tablets (30-count) under a firm fixed-price contract with an ultimate completion date of July 24, 2025. This non-competitive, non-set-aside award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical distributor,...
- The Defense Logistics Agency awarded a delivery order valued at $1,470.52 to AmerisourceBergen Drug Corp for Veozah 45 mg tablets (30-unit supply), with an ultimate completion date of July 25, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military...
- This delivery order, awarded July 31, 2025, by the Defense Logistics Agency to AmerisourceBergen Drug Corp, provides 30 tablets of Veozah 45 mg with a ceiling value of $1,846.62 and completion date of August 1, 2025. The order represents a competitively awarded, firm fixed-price transaction with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs across military and veteran...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,798.72 firm fixed-price delivery order is for the supply of VEOZAH 45 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of January 14, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
- The Defense Logistics Agency awarded a delivery order valued at $1,038.28 to AmerisourceBergen Drug Corp for Veozah 45 mg tablets (30-count) on July 23, 2025, with completion targeted for July 24, 2025. This firm fixed-price delivery order represents a small-value pharmaceutical transaction under a competitive award with no set-aside designation. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $12,719.67 to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of VEOZAH 45 mg tablets in 30-count packages. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of July 28, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Veozah 45 mg tablets (30-count packages) under a firm fixed-price arrangement. The contract ceiling value is $6,509.38, with an ultimate completion date of July 31, 2025. This delivery order represents a non-set-aside, competitively awarded transaction executed through AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVFW3Delivery Order
AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order contract on July 29, 2025, for the supply of Veozah 45 mg tablets (30-count) valued at $1,246.98. This firm fixed-price delivery order is funded by the Defense Logistics Agency (DLA), a component of the Department of Defense responsible for supplying pharmaceuticals and medical materials to military healthcare systems worldwide. The contract is non-competitive and represents a child award under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a maximum value of $999,999,999.00 and extends through December 2026. The place of performance is established in Conshohocken, Pennsylvania, with an ultimate completion date of July 30, 2025. This delivery order exemplifies AmerisourceBergen's role as a critical pharmaceutical vendor within the federal supply chain, providing brand-name and generic medications to support military and veteran healthcare requirements. The award of Veozah, a recently FDA-approved menopausal symptom treatment, demonstrates the company's capability to deliver contemporary pharmaceutical products to defense healthcare systems. As a major pharmaceutical distributor, AmerisourceBergen maintains a comprehensive portfolio of medical commodities spanning multiple therapeutic domains and continues to serve as a prime vendor through both established contract vehicles and new competitive opportunities, including the planned Pharmaceutical Prime Vendor Global Program Generation V contracts under which DLA intends to make awards to multiple regional contractors.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 7/29/25 |